Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review.
Anticancer Res
; 41(12): 5865-5871, 2021 Dec.
Article
em En
| MEDLINE
| ID: mdl-34848441
ABSTRACT
BACKGROUND/AIM:
Recurrent osteosarcoma is recalcitrant with poor response rates to first-line chemotherapy due to heterogeneity and metastatic potential. This disease requires novel drug discovery and precision treatment. MATERIALS ANDMETHODS:
The osteosarcoma patient-derived orthotopic xenograft (PDOX) mouse model mimics the clinical disease and has identified effective clinically-approved drugs and experimental agents, especially drug combinations, that hold much clinical promise.RESULTS:
Effective treatment for drug-resistant osteosarcoma includes regorafenib, as monotherapy, and temozolomide-irinotecan, trabectedin-irinotecan, sorafenib-everolimus, sorafenib-palbociclib, and olaratumab-doxorubicin-cisplatinum, as combinations.CONCLUSION:
The PDOX model can be used to improve the outcome of osteosarcoma patients, including individualized, precision therapy.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ósseas
/
Ensaios de Seleção de Medicamentos Antitumorais
/
Osteossarcoma
/
Ensaios Antitumorais Modelo de Xenoenxerto
/
Descoberta de Drogas
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
2021
Tipo de documento:
Article